ONS vs. PROK, PRME, ALLO, NVAX, VALN, HLVX, CABA, EXAI, FATE, and ALEC
Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include ProKidney (PROK), Prime Medicine (PRME), Allogene Therapeutics (ALLO), Novavax (NVAX), Valneva (VALN), HilleVax (HLVX), Cabaletta Bio (CABA), Exscientia (EXAI), Fate Therapeutics (FATE), and Alector (ALEC). These companies are all part of the "medical" sector.
ProKidney (NASDAQ:PROK) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
ProKidney has higher earnings, but lower revenue than Oncobiologics.
ProKidney has a net margin of 0.00% compared to ProKidney's net margin of -464.47%.
Oncobiologics received 168 more outperform votes than ProKidney when rated by MarketBeat users. However, 66.67% of users gave ProKidney an outperform vote while only 63.74% of users gave Oncobiologics an outperform vote.
ProKidney currently has a consensus price target of $9.50, indicating a potential upside of 348.11%. Given Oncobiologics' higher possible upside, research analysts clearly believe ProKidney is more favorable than Oncobiologics.
51.6% of ProKidney shares are held by institutional investors. Comparatively, 7.2% of Oncobiologics shares are held by institutional investors. 45.0% of ProKidney shares are held by company insiders. Comparatively, 11.5% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
ProKidney has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500.
In the previous week, ProKidney had 9 more articles in the media than Oncobiologics. MarketBeat recorded 9 mentions for ProKidney and 0 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.42 beat ProKidney's score of 0.00 indicating that ProKidney is being referred to more favorably in the media.
Summary
ProKidney beats Oncobiologics on 11 of the 13 factors compared between the two stocks.
Get Oncobiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncobiologics Competitors List
Related Companies and Tools
